GLA-AF, an Emulsion-Free Vaccine Adjuvant for Pandemic Influenza

Differential Activation of Human TLR4 by Escherichia coli and Shigella flexneri 2a Lipopolysaccharide: Combined Effects of Lipid A Acylation State and TLR4 Polymorphisms on Signaling

(2014) P. Rallabhandi et al.   JOURNAL OF IMMUNOLOGY

Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis

(2013) Mark T. Orr et al.   JOURNAL OF CONTROLLED RELEASE

Limited airborne transmission of H7N9 influenza A virus between ferrets

(2013) Mathilde Richard et al.   NATURE

The genesis and source of the H7N9 influenza viruses causing human infections in China

(2013) Tommy Tsan-Yuk Lam et al.   NATURE

Association between H1N1 vaccination and narcolepsy-cataplexy: Flu to sleep

(2013) S. V. Kothare et al.   NEUROLOGY

H7N9 Influenza Viruses Are Transmissible in Ferrets by Respiratory Droplet

(2013) Q. Zhang et al.   SCIENCE

Probable person to person transmission of novel avian influenza A (H7N9) virus in Eastern China, 2013: epidemiological investigation

(2013) X. Qi et al.   BMJ-British Medical Journal

AS03 Adjuvanted AH1N1 Vaccine Associated with an Abrupt Increase in the Incidence of Childhood Narcolepsy in Finland

(2012) Hanna Nohynek et al.   PLoS One

The mechanism of action of MF59 – An innately attractive adjuvant formulation

(2012) D.T. O’Hagan et al.   VACCINE

The incidence of narcolepsy in Europe: Before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns

(2012) Leonoor Wijnans et al.   VACCINE

The ferret as a model organism to study influenza A virus infection

(2011) J. A. Belser et al.   Disease Models & Mechanisms

Hallmarks of CD4 T cell immunity against influenza

(2011) K. K. McKinstry et al.   JOURNAL OF INTERNAL MEDICINE

Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant

(2011) Rhea N. Coler et al.   PLoS One

Immunogenicity and Safety of MF59-Adjuvanted H5N1 Influenza Vaccine From Infancy to Adolescence

(2010) T. Vesikari et al.   PEDIATRICS

Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations

(2009) Ryan C. Anderson et al.   COLLOIDS AND SURFACES B-BIOINTERFACES

MF59®-Adjuvanted H5N1 Vaccine Induces Immunologic Memory and Heterotypic Antibody Responses in Non-Elderly and Elderly Adults

(2009) Angelika Banzhoff et al.   PLoS One

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine

(2009) G. Galli et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels

(2009) G. Galli et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults

(2009) Tino F. Schwarz et al.   VACCINE

MF59-adjuvanted versus non-adjuvanted influenza vaccines: Integrated analysis from a large safety database

(2009) Michele Pellegrini et al.   VACCINE

Priming with AS03A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: An open non-randomised extension of a double-blind randomised primary study

(2009) Isabel Leroux-Roels et al.   VACCINE